Biotinylated Human HMGB1 Protein (Primary Amine Labeling)
Catalog No: HMGB1-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human HMGB1 Protein (Primary Amine Labeling) is expressed in HEK293 cells with a His tag at the C-terminus. It contains amino acid residues Met1-Glu215 (UniProt accession: P09429-1).
Product Details
- Molecular Aliases
- HMGB1; HMG1; HMG3; SBP-1; HMG-1; SBP1
- Protein Length
- Met1-Glu215
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 26 kDa. Due to glycosylation, the protein migrates to 32-36 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per ug by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human HMGB1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human HMGB1 is greater than 95% as determined by SEC-HPLC.
Human AGER, His Tag immobilized on CM5 Chip can bind Biotinylated Human HMGB1, His Tag with an affinity constant of 2.60 μM as determined in SPR assay (Biacore T200).
Background
High-mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that promotes inflammation when released extracellularly after cellular activation, stress, damage or death. HMGB1 operates as one of the most intriguing molecules in inflammatory disorders via recently elucidated signal and molecular transport mechanisms. Treatments based on antagonists specifically targeting extracellular HMGB1 have generated encouraging results in a wide number of experimental models of infectious and sterile inflammation.
References
- Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. 2013 Jun;93(6):865-73. doi: 10.1189/jlb.1212662. Epub 2013 Feb 27. PMID: 23446148; PMCID: PMC4051189.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.